Clinical trials: Thalidomide, completed
Hepatocellular Cancer (HCC)
Effect of TCC Cocktail Combined With TACE Versus TACE Alone on Survival in uHCC Patients
This is a multicenter, retrospective cohort study that aims to evaluate the efficacy and safety of a triple-drug cocktail (TCC), consisting of Thalidomide, Carmofur, and Compound Mylabris Capsules (CMC), in combination with…
- Trial name
- NCT07321613
- Testing
- Thalidomide (50mg), carmofur, compound mylabris capsule
- Where
- China
- Volunteers
- 545 people
- Sponsor
- Shanghai Zhongshan Hospital
Multiple Myeloma
Study of Carfilzomib for Multiple Myeloma Patients Who Are Relapsed/Refractory to Bortezomib-containing Treatments
This is a phase I/II multicenter, open label, nonrandomized study for patients with Multiple Myeloma (MM) who will receive treatment with carfilzomib in place of bortezomib using the same bortezomib-containing combination regimen…
- Trial name
- NCT01365559
- Testing
- Group A: Carfilzomib & Non-IMiD Regimen, Group B: Carfilzomib & IMiD containing regimen.
- Where
- 9 sites in United States
- Volunteers
- 39 people
- Sponsor
- Oncotherapeutics
Multiple Myeloma and Plasma Cell Neoplasm, Neurotoxicity
Bortezomib, Thalidomide, and Dexamethasone After Melphalan and Stem Cell Transplant in Treating Patients With Stage I-III Multiple Myeloma
RATIONALE: Bortezomib and thalidomide may stop the growth of multiple myeloma by blocking blood flow to the cancer. Bortezomib may also stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
- Trial name
- NCT00792142
- Testing
- bortezomib, dexamethasone, melphalan
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- City of Hope Medical Center
HIV Infections, Mycobacterium Infections
Phase II Placebo Controlled Study of Thalidomide in Patients With Mycobacterial and HIV Infections
OBJECTIVES: I. Evaluate whether thalidomide modulates toxic host inflammatory responses in patients receiving antitubercular therapy. II.
- Conditions
- HIV Infections, Mycobacterium Infections, Tuberculosis
- Trial name
- NCT00004276
- Testing
- thalidomide
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- National Center for Research Resources (NCRR)
Liver Cancer
Thalidomide Plus Interferon Alfa in Treating Patients With Progressive Liver Cancer That Cannot be Surgically Removed
Phase II trial to study the effectiveness of thalidomide plus interferon alfa in treating patients who have progressive liver cancer that cannot be surgically removed.
- Trial name
- NCT00006006
- Testing
- recombinant interferon alfa, thalidomide
- Where
- 2 sites in United States
- Volunteers
- 38 people
- Sponsor
- National Cancer Institute (NCI)
Multiple Myeloma
STUDY THAT COMPARE 3 ARM: MLN9708 DEXAMETHASONE, MLN9708 CYCLOPHOSPHAMIDE AND DEXAMETHASONE, MLN9708 THALIDOMIDE AND DEXAMETHASONE FOLLOWED BY MAINTENANCE WITH MLN9708 IN NEWLY DIAGNOSED ELDERLY MULTIPLE MYELOMA PATIENTS
This study will evaluate the safety and the efficacy of the MLN-DEXAMETHASONE, MLN-DEXAMETHASONE-CYCLOPHOSPHAMIDE, or MLN- THALIDOMIDE-DEXAMETHASONE induction combinations, followed by MLN maintenance in newly diagnosed elderly…
- Trial name
- NCT02586038
- Testing
- MLN9708, Dexamethasone, Cyclophosphamide
- Where
- Italy
- Volunteers
- 175 people
- Sponsor
- Mario Boccadoro
Multiple Myeloma
Thalidomide for Multiple Myeloma
The objective of this protocol is to assess therapeutic activity of thalidomide in previously untreated patients with asymptomatic multiple myeloma.
- Trial name
- NCT00038233
- Testing
- Thalidomide
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- M.D. Anderson Cancer Center
Multiple Myeloma
Thalidomide 100 mg/Day Versus Thalidomide 400 mg/Day in Relapse Refractory Multiple Myeloma
The objective of this study is to show that thalidomide at a dose of 100 mg/d (with remedial treatment with dexamethasone if a progression occurs) is equivalent in terms of efficacy with thalidomide at 400 mg/d (with remedial…
- Trial name
- NCT00657488
- Testing
- Thalidomide
- Where
- 49 sites in Belgium, France
- Volunteers
- 400 people
- Sponsor
- Celgene
Multiple Myeloma
D.T. PACE Versus High Dose Melphalan and Autologous Transplant in Patients With Previously Treated Multiple Myeloma
This study has been designed to evaluate whether combination chemotherapy and "anti-angiogenesis" therapy with thalidomide is equal or superior to autologous transplantation for the treatment of multiple myeloma.
- Trial name
- NCT00083876
- Testing
- Thalidomide
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- University of Arkansas
Beta-Thalassemia
Comparison Of Efficacy And Safety Of Thalidomide Vs Hydroxyurea In Thalassemia Patients: A Single-Centre Pilot Study.
The goal of this study is to compare the effectiveness and safety of two hemoglobin F inducer. This is single centered interventional pilot study is to compare the efficacy and safety parameters in beta thalassemia patients.
- Trial name
- NCT06239389
- Testing
- Thalidomide 100mg, Hydroxyurea
- Where
- Pakistan
- Volunteers
- 24 people
- Sponsor
- National Institute of Blood and Marrow Transplant (NIBMT), Pakistan
Graft Versus Host Disease, Unspecified Adult Solid Tumor, Protocol Specific
Thalidomide in Treating Patients With Chronic Graft-Versus-Host Disease Following Bone Marrow Transplant
RATIONALE: Thalidomide may interfere with the body's ability to recognize transplanted bone marrow cells as foreign and may help treat patients with graft-versus-host disease.
- Conditions
- Graft Versus Host Disease, Unspecified Adult Solid Tumor, Protocol Specific, Unspecified Childhood Solid Tumor, Protocol Specific
- Trial name
- NCT00003894
- Testing
- thalidomide
- Where
- 10 sites in United States
- Volunteers
- 36 people
- Sponsor
- Roswell Park Cancer Institute
Cutaneous Lupus Erythematosus (CLE)
Evaluation of Lenalidomide (REVLIMID®) to Treat Subjects With Cutaneous Lupus Erythematosus (CLE)
This study is being conducted to evaluate the safety and effectiveness of lenalidomide (Revlimid®) in subjects with Cutaneous Lupus Erythematosus (CLE).
- Trial name
- NCT00633945
- Testing
- Lenalidomide
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Pennsylvania
Prostatic Neoplasm
A Randomized Phase II Study of Oral Thalidomide in Patients With Hormone-Refractory Prostate Cancer
This is a phase II study designed to evaluate the potential clinical efficacy of thalidomide in patients with hormone-refractory prostate cancer.
- Trial name
- NCT00001446
- Testing
- thalidomide
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- National Cancer Institute (NCI)
Brain and Central Nervous System Tumors
Temozolomide, Thalidomide, and Celecoxib Following Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Thalidomide and celecoxib may stop the growth of tumor cells by stopping blood flow to the tumor and may…
- Trial name
- NCT00047294
- Testing
- celecoxib, temozolomide, thalidomide
- Where
- 4 sites in United States
- Sponsor
- Dana-Farber Cancer Institute
Multiple Myeloma and Plasma Cell Neoplasm
Arsenic Trioxide and Ascorbic Acid Combined With Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia
RATIONALE: Drugs used in chemotherapy, such as arsenic trioxide and dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00258245
- Testing
- ascorbic acid, arsenic trioxide, bortezomib
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Melanoma (Skin)
S0508: Thalidomide and Temozolomide in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery
RATIONALE: Thalidomide may stop the growth of melanoma by blocking blood flow to the tumor. It may also stimulate the immune system in different ways and stop tumor cells from growing.
- Trial name
- NCT00104988
- Testing
- temozolomide, thalidomide
- Where
- 132 sites in United States
- Volunteers
- 64 people
- Sponsor
- SWOG Cancer Research Network
Telangiectasia, Hereditary Hemorrhagic
Pomalidomide for the Treatment of Bleeding in HHT
This is a Phase II placebo-controlled double-blind study of pomalidomide in patients with hereditary hemorrhagic telangiectasia (HHT) with moderate to severe epistaxis who have anemia and/or require parenteral iron infusions or…
- Trial name
- PATH-HHT (NCT03910244)
- Testing
- Pomalidomide Oral Product
- Where
- 14 sites in United States
- Volunteers
- 145 people
- Sponsor
- The Cleveland Clinic
Non-Hodgkin's Lymphoma
Phase II Study of RT-PEPC in Relapsed Mantle Cell Lymphoma
Primary Objective: Evaluate the clinical activity of the RT-PEPC combination regimen (rituximab, thalidomide, and prednisone, etoposide, procarbazine, cyclophosphamide) in patients with relapsed mantle cell lymphoma.
- Trial name
- NCT00151281
- Testing
- PEPC, Thalidomide, Rituximab
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Weill Medical College of Cornell University
HIV Infections
Using the Drug Thalidomide to Stimulate T Cells in HIV-Infected People
Despite treatment with anti-HIV drugs, people infected with HIV continue to have problems with their immune systems. This study will evaluate whether the drug thalidomide, which stimulates the immune system's T cells, can improve…
- Trial name
- NCT00053430
- Testing
- Thalidomide
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Carcinoma of the Appendix, Colorectal Cancer
Thalidomide in Treating Patients Who Have Undergone Surgery and Chemotherapy for Cancer That Has Spread Throughout the Abdomen Due to Colorectal Cancer or Appendix Cancer
RATIONALE: Thalidomide may stop the growth of tumor cells by blocking blood flow to the tumor. Giving thalidomide after surgery and chemotherapy may kill any remaining tumor cells.
- Trial name
- NCT00310076
- Testing
- thalidomide, surgery
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Wake Forest University Health Sciences